Dulaglutide
GLP-1 receptor agonist (weekly)
A once-weekly GLP-1 with established CV outcomes data.
Half-life
~ 5 days (once-weekly dosing)
Mol. weight
~ 59.3 kDa (Fc-fusion construct)
Sequence
GLP-1 analog fused to modified IgG4 Fc
Discussions
0 threads
Overview
Dulaglutide is a once-weekly GLP-1 receptor agonist approved for type 2 diabetes, with cardiovascular outcomes established in the REWIND trial. It uses a Fc-fusion protein approach to achieve its week-long half-life, providing an alternative long-acting option within the GLP-1 class.
Mechanism of action
Dulaglutide consists of two GLP-1 analog molecules each fused to a modified human IgG4 Fc fragment, which extends the half-life to ~5 days and enables once-weekly dosing. It acts on the GLP-1 receptor to increase glucose-dependent insulin secretion, suppress glucagon, slow gastric emptying, and reduce appetite.
Researched benefits
- Once-weekly dosing convenience
- Cardiovascular outcomes benefit (REWIND trial) in type 2 diabetes
- Improved glycemic control
- Long-acting alternative within the GLP-1 class
Considerations
- Gastrointestinal side effects common
- Primarily studied in type 2 diabetes (not obesity-approved at standard doses)
- Rare risks: pancreatitis, gallbladder events
- Requires medical supervision
Key Academic Literature & Studies
Search more in PubMedPeer-reviewed citations and clinical trials evaluating Dulaglutide in scientific literature.
Query PubMed for recent peer-reviewed preclinical and clinical publications on Dulaglutide:
View Dulaglutide index on PubMed (NCBI)